

University of Groningen

Compartmentalized PDE4A5 signaling impairs hippocampal synaptic plasticity and long-term memory

Havekes, Robbert; Park, Alan J.; Tolentino, Rosa E.; Bruinenberg, Vibeke M.; Tudor, Jennifer C.; Lee, Yool; Hansen, Rolf T.; Guercio, Leonardo A.; Linton, Edward; Neves-Zaph, Susana R.

Published in:
The Journal of Neuroscience

DOI:
[10.1523/JNEUROSCI.0248-16.2016](https://doi.org/10.1523/JNEUROSCI.0248-16.2016)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Havekes, R., Park, A. J., Tolentino, R. E., Bruinenberg, V. M., Tudor, J. C., Lee, Y., Hansen, R. T., Guercio, L. A., Linton, E., Neves-Zaph, S. R., Meerlo, P., Baillie, G. S., Houslay, M. D., & Abel, T. (2016). Compartmentalized PDE4A5 signaling impairs hippocampal synaptic plasticity and long-term memory. *The Journal of Neuroscience*, 36(34), 8936-8946. <https://doi.org/10.1523/JNEUROSCI.0248-16.2016>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory

Robbert Havekes,^{1,2} Alan J. Park,² Rosa E. Tolentino,³ Vibeke M. Bruinenberg,¹ Jennifer C. Tudor,² Yool Lee,³ Rolf T. Hansen,² Leonardo A. Guercio,² Edward Linton,² Susana R. Neves-Zaph,⁴ Peter Meerlo,¹ George S. Baillie,⁵ Miles D. Houslay,⁶ and Ted Abel²

¹Groningen Institute for Evolutionary Life Sciences, University of Groningen, 9700 AB, Groningen, The Netherlands, ²Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, ³Department of Systems Pharmacology and Translational Therapeutics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, ⁴Departments of Pharmacology and Systems Therapeutics, Friedman Brain Institute, and System Biology Center New York, Icahn School of Medicine at Mount Sinai, New York, New York 10029, ⁵Institute of Cardiovascular and Medical Science, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom, and ⁶Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom

Alterations in cAMP signaling are thought to contribute to neurocognitive and neuropsychiatric disorders. Members of the cAMP-specific phosphodiesterase 4 (PDE4) family, which contains >25 different isoforms, play a key role in determining spatial cAMP degradation so as to orchestrate compartmentalized cAMP signaling in cells. Each isoform binds to a different set of protein complexes through its unique N-terminal domain, thereby leading to targeted degradation of cAMP in specific intracellular compartments. However, the functional role of specific compartmentalized PDE4 isoforms has not been examined *in vivo*. Here, we show that increasing protein levels of the PDE4A5 isoform in mouse hippocampal excitatory neurons impairs a long-lasting form of hippocampal synaptic plasticity and attenuates hippocampus-dependent long-term memories without affecting anxiety. In contrast, viral expression of a truncated version of PDE4A5, which lacks the unique N-terminal targeting domain, does not affect long-term memory. Further, overexpression of the PDE4A1 isoform, which targets a different subset of signalosomes, leaves memory undisturbed. Fluorescence resonance energy transfer sensor-based cAMP measurements reveal that the full-length PDE4A5, in contrast to the truncated form, hampers forskolin-mediated increases in neuronal cAMP levels. Our study indicates that the unique N-terminal localization domain of PDE4A5 is essential for the targeting of specific cAMP-dependent signaling underlying synaptic plasticity and memory. The development of compounds to disrupt the compartmentalization of individual PDE4 isoforms by targeting their unique N-terminal domains may provide a fruitful approach to prevent cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with alterations in cAMP signaling.

Key words: cAMP; hippocampus; LTP; memory; PDE; phosphodiesterase

Significance Statement

Neurons exhibit localized signaling processes that enable biochemical cascades to be activated selectively in specific subcellular compartments. The phosphodiesterase 4 (PDE4) family coordinates the degradation of cAMP, leading to the local attenuation of cAMP-dependent signaling pathways. Sleep deprivation leads to increased hippocampal expression of the PDE4A5 isoform. Here, we explored whether PDE4A5 overexpression mimics behavioral and synaptic plasticity phenotypes associated with sleep deprivation. Viral expression of PDE4A5 in hippocampal neurons impairs long-term potentiation and attenuates the formation of hippocampus-dependent long-term memories. Our findings suggest that PDE4A5 is a molecular constraint on cognitive processes and may contribute to the development of novel therapeutic approaches to prevent cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with alterations in cAMP signaling.

Introduction

The cAMP signaling pathway plays an essential role in synaptic plasticity and memory (Havekes and Abel, 2009). Local degradation of cAMP within specific intracellular compartments is precisely orchestrated by cAMP-degrading phosphodiesterases (PDEs; Houslay, 2010; Mika et al., 2012). Isoforms of the PDE4

subfamily have a prominent role in regulating cAMP signaling in the mammalian brain (Houslay and Adams, 2003; O'Donnell and Zhang, 2004; Sanderson and Sher, 2013), in *Drosophila* (Conti and Jin, 1999), and in the *Aplysia* nervous system (Park et al., 2005). Although the catalytic cAMP-degrading domain of the PDE4 isoforms is highly conserved, all of the >25 described iso-

forms have a unique N-terminal domain that targets each isoform to specific intracellular compartments, where it binds to a unique set of protein complexes (Houslay, 2010). Pharmacological suppression of PDE4 activity promotes synaptic plasticity and memory (Randt et al., 1982; Barad et al., 1998; Rutten et al., 2009; Werenicz et al., 2012). The PDE4 selective inhibitor, rolipram, prevents memory deficits associated with sleep loss (Vecsey et al., 2009), traumatic brain injury (Titus et al., 2013), aging (Wimmer et al., 2012), muscarinic or NMDA receptor blockade (Egawa et al., 1997; Zhang and O'Donnell, 2000; Wiescholleck and Manahan-Vaughan, 2012), and mouse models of Alzheimer's disease (Gong et al., 2004; Reneerkens et al., 2009; Richter et al., 2013). However, the clinical use of broad PDE4 inhibitors is limited due to undesirable side effects, including emesis and diarrhea (Zeller et al., 1984; Bertolino et al., 1988; Spina, 2008). To circumvent these issues, which compromise the clinical use of pan-PDE4 inhibitors, studies are needed to identify which PDE4 isoforms target signaling complexes critical for cognitive processes and then to exploit such data to develop isoform-specific inhibitor approaches.

The PDE4 family is encoded by four genes (PDE4A–PDE4D; Houslay, 2010). PDE4B knock-out mice perform normally in hippocampus-dependent learning paradigms (Siuciak et al., 2008), but display an anxiogenic-like phenotype (Zhang et al., 2008), a phenotype also observed in mice lacking PDE4A isoforms (Hansen et al., 2014). Importantly, recent work revealed that the PDE4A family is not involved in emesis (Hansen et al., 2014), in contrast to the PDE4D subfamily (Robichaud et al., 2002). Mice lacking all PDE4D isoforms display either memory enhancements or impairments, depending on the task used (Rutten et al., 2008; Li et al., 2011). Although these mutant mouse models provide insight into the role of PDE4 families in plasticity and memory, they lack the resolution needed to identify which individual isoforms orchestrate the observed behavioral and cognitive phenotypes.

The importance of studying individual PDE family members is underscored by the complex regulation of isoform expression, which includes multiple promoters, alternative mRNA splicing, and alternative translational initiation sequences (Houslay et al., 2007). Expression levels of individual PDE4 isoforms are altered

in traumatic brain injury (Oliva et al., 2012), autism spectrum disorders, schizophrenia, and bipolar disorder (Braun et al., 2007; Fatemi et al., 2008a,b) by electroconvulsive shock delivery and treatment with antidepressants (Takahashi et al., 1999; D'Sa et al., 2005). Changes in cerebellar expression levels of PDE4A4, the human ortholog of rodent PDE4A5, are observed in patients with autism or bipolar disorder (Braun et al., 2007; Fatemi et al., 2008a). Further, PDE4A4/5 levels are upregulated in the lung tissue of patients with chronic obstructive pulmonary disease (COPD; Barber et al., 2004). Interestingly, COPD patients frequently experience sleep loss (Crinion and McNicholas, 2014), a condition that elevates PDE4A5 protein expression in the mouse hippocampus without affecting levels of other PDE4 isoforms (Vecsey et al., 2009). Although these findings suggest that memory impairments may be associated with altered PDE4A4/5 expression, it is unclear whether PDE4A4/5 in healthy conditions targets signaling mechanisms that are critical for memory. In the present study, we used a viral approach to increase the mouse PDE4A5 protein levels selectively in hippocampal excitatory neurons *in vivo* to assess the impact of elevated PDE4A5 expression on hippocampal synaptic plasticity and memory.

Materials and Methods

Subjects. C57BL/6J male mice (2–3 months of age) were obtained from The Jackson Laboratory at 6 weeks of age and housed in groups of four with littermates on a 12 h light/dark schedule with lights on at 7:00 A.M. [zeitgeber time 0 (ZT0)]. Mice had food and water available *ad libitum*. Mice underwent surgery at 8–12 weeks of age, were individually housed for 5 d to recover from surgery, and then were pair housed throughout the experiment. For all behavioral experiments, mice were handled in the experimental room for 5 d for 1 min/d. All experiments were conducted according to National Institutes of Health (NIH) *Guide for the Care and Use of Laboratory Animals* and were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

Viral injections. The adeno-associated viruses (AAVs) were injected using a nanofil 33 ga beveled needles (WPI) attached to a 10 μ l Hamilton syringe controlled by a microsyringe pump (model UMP3, WPI) at the following sites (anteroposterior, -1.9 mm from bregma; dorsoventral, ± 1.5 mm from bregma; and 1.5 mm below bregma), as described previously (Havekes et al., 2014). The needle was slowly lowered to the target site over the course of 3 min and remained at the target site for 1 min before the beginning of the injection (0.2 μ l/min). Approximately 1 μ l (corrected for genome copy number between constructs) was injected per hippocampus. After the injection, the needle remained at the target site for 1 min and then was slowly removed over a 5 min period.

DNA manipulation and virus constructs. Full-length rat PDE4A5 and mouse PDE4A1 constructs were based on GenBank accession numbers L27057.1 and M26715. The truncated PDE4A5 that lacks the first 303 bp encoding the isoform-unique N-terminal domain (referred to as PDE4A5 $^{\Delta 4}$; Bolger et al., 2003) was generated using standard PCR cloning procedures and the Stratagene PfuUltra High-Fidelity DNA polymerase. pAAV $_9$ -CaMKII α 0.4-PDE4A5-VSV, pAAV $_9$ -CaMKII α 0.4-PDE4A5 $^{\Delta 4}$ -HA, pAAV $_9$ -CaMKII α 0.4-PDE4A1-HA, and pAAV $_9$ -CaMKII α 0.4-eGFP were produced through standard methods and packaged by the Penn Vector Core at the University of Pennsylvania. Titers ranged from 1.06×10^{13} to 2.02×10^{13} genome copy numbers. A 0.4 kb CaMKII α promoter fragment (Dittgen et al., 2004) was used to drive expression selectively in excitatory neurons.

Biochemistry. ELISA-based assay kits (ENZO Life Sciences) were used to measure cAMP content following the manufacturer instructions. PDE activity assays and Western blots were conducted as described previously (Vecsey et al., 2009). For all other protein analyses, tissue lysates were prepared in Tris 50 mM, pH 9, sodium deoxycholate 1%, sodium fluoride 50 mM, activated sodium vanadate 20 μ M, EDTA 20 μ M, and β -glycerophosphate 40 μ M. Protease inhibitors (Roche) and phosphatase inhibitors (Thermo Scientific) were added to the freshly prepared buffer just before tissue lysates. Samples were centrifuged for 10 min at

Received Jan. 23, 2016; revised June 26, 2016; accepted June 29, 2016.

Author contributions: R.H., A.J.P., J.C.T., R.T.H., S.R.N.-Z., P.M., G.S.B., M.D.H., and T.A. designed research; R.H., A.J.P., R.E.T., V.M.B., J.C.T., Y.L., L.A.G., and E.L. performed research; G.S.B. and M.D.H. contributed unpublished reagents/analytic tools; R.H., A.J.P., R.E.T., V.M.B., J.C.T., and S.R.N.-Z. analyzed data; R.H., P.M., M.D.H., and T.A. wrote the paper.

This research was supported by Netherlands Organization for Scientific Research NWO-Rubicon Grant 825.07.029 (to R.H.); the University of Pennsylvania Research Foundation (to R.H. and T.A.); National Institutes of Health Grants 1R01-MH-086415-9 (to T.A.), AG-017628 (to T.A., A.J. Pack Principal Investigator), 5K12-GM-081529 (to J.C.T., Y. Paterson Principal Investigator), and 5R01-DK-087650 (to S.R.N.-Z.); and Systems Biology Center of New York Grant PSDGM071558 (to S.R.N.-Z.). G.S.B. is supported by Medical Research Council Grant MR/J007412/1. R.H. is supported by the Einstein Foundation. T.A. is the Brush Family Professor of Biology at the University of Pennsylvania. We thank other Abel laboratory members for their help with these experiments and for their comments on this manuscript. We also thank Jin Zhang for providing pUCUE3.

The authors declare no competing financial interests.

This article is freely available online through the *J. Neurosci.* Author Open Choice option.

Correspondence should be addressed to either of the following: Robbert Havekes, Groningen Institute for Evolutionary Life Sciences (GELIFES), University of Groningen, 9700 AB, Groningen, The Netherlands, E-mail: r.havekes@rug.nl; or Ted Abel, Department of Biology, University of Pennsylvania, Philadelphia, PA 19104-6018. E-mail: abele@sas.upenn.edu.

A. J. Park's present address: Department of Psychiatry, Columbia University, and the New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032.

DOI:10.1523/JNEUROSCI.0248-16.2016

Copyright © 2016 Havekes et al.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

13,000 \times g at 4°C, and supernatant was collected. Protein concentration of the samples was measured using the Bradford method. LDS sample buffer (Nupage, Invitrogen) including β -mercaptoethanol was added, and samples were boiled for 5 min before loading on Criterion TGX 18-well 4–20% gels (Bio-Rad). After electrophoresis, proteins were transferred to PVDF membrane followed by blocking for 1 h in 5% milk in TBST. After blocking, membranes were incubated in 5% milk or BSA with one of the following antibodies: GAPDH (1:1000; K1511, Santa Cruz Biotechnology); PDE4A (1:1000; Vecsey et al., 2009); PDE4A5 (1:1000; Vecsey et al., 2009); HA tag (1:1000; catalog #1867423, Roche); and vesicular stomatitis virus (VSV) tag (1:3000; catalog #1874, Abcam). After incubation with the primary antibodies, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature (1:1000, mouse secondary antibody, sc-2318, Santa Cruz Biotechnology; 1:5000, rabbit secondary antibody, sc-2030, Santa Cruz Biotechnology; rat secondary antibody, sc-2032, 1:1000, Santa Cruz Biotechnology). The immunoreactive bands were captured on autoradiography film (Kodak) and analyzed using ImageJ (NIH).

Immunohistochemistry. Immunohistochemistry was conducted as described previously (Isiegas et al., 2008). The following antibodies or combinations of antibodies were used: PDE4A5 (1:200; Vecsey et al., 2009); HA tag (1:200; catalog #1867423, Roche); VSV tag (1:2000; catalog #1874, Abcam); GFAP-Alexa Fluor 488 (1:300; catalog #43202, Millipore); followed by the appropriate Alexa Fluor-conjugated secondary antibodies (1:1000; Invitrogen) for 1 h at room temperature. Images were captured using a Leica SP8 confocal microscope. Immunolabeling for cAMP was conducted using cAMP antibodies (1:200; catalog #07-1497, Millipore) in combination with the DAB procedure (Havekes et al., 2007). Optical density measurements in the corpus callosum were used to correct for background labeling. DAB images were captured using a Fisher Scientific light microscope, and optical density measurements were conducted using ImageJ.

Behavioral assays. The object-place recognition task, fear-conditioning task, open field task, and zero maze task were conducted as described previously (Tretter et al., 2009; Oliveira et al., 2010; Havekes et al., 2012b, 2014). Training and testing was conducted between ZT0 and ZT4.

Cell culture studies. Neurons (100,000/ml of C57BL/6J mouse hippocampus) were plated in a 24-well dish with coated coverslips. A week later, we transduced the neurons with AAV vectors expressing VSV-tagged PDE4A5 (PDE4A5-VSVg) and HA-tagged PDE4A5 N-terminal truncated mutant (PDE4A5delta4-HA). At 7 d post-transduction, the neuronal cells were fixed with 4% paraformaldehyde in PBS and incubated with anti-VSV (ab1874, Abcam) and anti-HA (ab130275, Abcam) antibodies for immunofluorescence analysis. The neuron samples were visualized with secondary antibodies conjugated with Alexa Fluor 488 and 568 dyes (ThermoFisher Scientific) using a fluorescence imaging microscope with GFP- and RFP-selective filter sets.

Electrophysiology. Field recordings in hippocampal slices were conducted as previously described (Havekes et al., 2012b).

Fluorescence resonance energy transfer sensor imaging. cAMP was measured using the ICUE3 biosensor, as described previously (DiPilato and Zhang, 2009). Primary rat hippocampal cultures were obtained as described previously (Neves et al., 2008). Primary hippocampal cultures (8–12 d *in vitro*) were transfected using Lipofectamine 2000 (Life Technologies) with pICUE3 (provided by Jin Zhang, Johns Hopkins University, Baltimore, MD) and mCherry alone, or pPDE4A5-full-mCherry or pPDE4A5-truncated-mCherry. Twenty-four hours later, neurons were preincubated for 60 min at 37°C with nifedipine (Sigma-Aldrich) and tetrodotoxin (Tocris Bioscience) to eliminate any calcium or depolarization-induced signaling. Neurons were then transferred to an imaging chamber maintained at 32°C and continually perfused with 1 \times HBSS (Life Technologies) containing 25 mM HEPES buffer (Life Technologies), 10 mM glucose, and 0.5 mM Trolox (Sigma-Aldrich). Multiple ICUE3- and mCherry-expressing neurons were selected. Transfected neurons were imaged every 60 s on an inverted Axio-Observer Z1 microscope (Zeiss) with an automated stage using AxioVision 4.8 software using a Plan-Apochromat 40 \times /1.3 oil-objective and a QuantEM electron-multiplying charge-coupled device camera (Photometrics), illuminated by a Colibri controlled LED system (Zeiss). At each time

point, images were acquired from the Cerulean and fluorescence resonance energy transfer (FRET) channels with the following settings: for Cerulean: excitation (ex), LED 455 nm; emission (em), 475/40 nm; for FRET: ex, LED 455 nm; em, 535/25 nm. The time course of the experiment contained the following three phases: 5–7 min baseline; 25 min of 50 μ M forskolin (FK; Tocris Bioscience); followed by 10 min of 100 μ M 3-isobutyl-1-methylxanthine (IBMX; Tocris Bioscience) to saturate the cAMP response. Images were converted into grayscale values, and the dendritic fluorescent intensities were measured with ImageJ after background correction. The ratio of Cerulean and FRET was calculated for each time point.

Statistical analyses. Data analysis was performed using SPSS version 20 (SPSS). Data were analyzed using one-way or two-way ANOVAs (in some cases with repeated measures as the within-subject variable), independent-sample *t* tests, paired *t* tests, or one-way ANOVAs combined with Tukey *post hoc* tests. Differences were considered statistically significant at $p < 0.05$. All data are plotted as the mean \pm SEM.

Results

Overexpression of PDE4A5 in hippocampal excitatory neurons increases PDE4 activity and reduces cAMP levels

Virally induced PDE4A5 expression was observed in excitatory neurons throughout the hippocampus (Fig. 1*A–E*). Double-labeling studies using GFAP as a marker for astrocytes suggested that expression was restricted to neurons (Fig. 1*F–H*). Biochemical analyses confirmed the virally induced increase in PDE4A5 protein levels in hippocampal lysates (eGFP, $n = 4$; PDE4A5, $n = 4$; $t_{(7)} = -6.84$; $p = 0.001$; Fig. 1*I*) and elevated PDE4 activity (eGFP, $n = 10$; PDE4A5, $n = 9$; $t_{(17)} = 13.67$; $p = 0.0001$; Fig. 1*J*), with a lack of a change in non-PDE4 cAMP hydrolyzing activity ($t_{(17)} = -0.77$; $p = 0.453$; Fig. 1*J*). Increased hippocampal PDE4 activity caused reduced cAMP levels in the hippocampus (eGFP, $n = 5$; PDE4A5, $n = 5$; $t_{(7)} = 3.94$; $p = 0.0056$; Fig. 2*A*), but not in either the prefrontal cortex or cerebellum ($t_{(7)} = 0.35$, $p = 0.732$, and $t_{(8)} = -1.16$, $p = 0.279$, respectively; Fig. 2*A*). A reduction in cAMP immunoreactivity was evident in all three major hippocampal regions (eGFP, $n = 8$; PDE4A5, $n = 8$; CA1, $t_{(14)} = 2.10$, $p = 0.029$; CA3, $t_{(14)} = 2.50$, $p = 0.026$; DG, $t_{(14)} = 2.51$, $p = 0.025$; Fig. 2*B,C*), but not in the amygdala (AMY; $t_{(14)} = -0.33$; $p = 0.372$; Fig. 2*B,C*). Together, these data indicate that the overexpression of PDE4A5 in hippocampal excitatory neurons increases PDE4 activity and reduces cAMP levels in the hippocampus without affecting cAMP content in other brain regions.

Elevated hippocampal PDE4A5 levels attenuate cAMP-dependent synaptic plasticity

Initial electrophysiological characterization of synaptic transmission in the Schaffer collateral–CA1 pathway involved measuring basal synaptic transmission and paired-pulse facilitation (PPF), an index of short-term plasticity. Increased PDE4A5 protein levels did not alter basal synaptic transmission (eGFP, $n = 8$; PDE4A5, $n = 8$; $t_{(14)} = 1.37$; $p = 0.192$; Fig. 3*A*) or PPF (eGFP, $n = 9$; PDE4A5, $n = 9$; ANOVA, effect of virus, $F_{(1,16)} = 0.024$, $p = 0.879$; Fig. 3*B*). Maximum fEPSP slopes were not significantly different between groups (eGFP, $n = 9$, -10.56 ± 1.12 mV/ms; PDE4A5, $n = 9$, -10.45 ± 1.55 mV/ms; $t_{(12)} = 0.06$; $p = 0.949$). Bath application of FK activates adenylyl cyclases, leading to increased intracellular cAMP levels and synaptic potentiation (Vecsey et al., 2009; Havekes et al., 2012b; Park et al., 2014). PDE4A5 overexpression reduces the synaptic potentiation following application of forskolin (50 μ M) with a significant reduction in the mean fEPSP slope over the last 20 min of the recording (eGFP, $175.7 \pm 17.7\%$; PDE4A5, $109.4 \pm 21.0\%$; $t_{(11)} = 2.42$; $p =$




Figure 1. Overexpression of PDE4A5 in hippocampal excitatory neurons increases PDE4A5 protein levels and PDE4 activity. **A**, Mice were bilaterally injected with AAV₅-CaMKII-eGFP or AAV₅-CaMKII-PDE4A5-VSV into the hippocampus. **B**, Viral PDE4A5 protein expression was restricted to the hippocampus. **C–E**, Viral expression of PDE4A5 was observed in all three major hippocampal subregions. **F–H**, Transgene expression was not observed in hippocampal astrocytes (PDE4A5-VSV, red; GFAP, green; bottom). **I**, A representative immunoblot for PDE4A5 protein levels. Viral overexpression of PDE4A5 leads to significantly higher PDE4A5 protein levels in hippocampal lysates. **J**, Overexpression of PDE4A5 significantly increases PDE4 activity without affecting non-PDE4 activity. All error bars denote SEM. *** $p = 0.001$, **** $p = 0.0001$.

0.035; Fig. 3C). This finding suggests that cAMP-dependent synaptic plasticity in the hippocampus is impaired by elevating PDE4A5 levels. In future studies, it will be interesting to determine whether PDE4A5 overexpression also reproduces deficits in other long-lasting forms of LTP known to be attenuated by sleep deprivation, such as LTP induced by spaced four-train or theta burst stimulation (Vecsey et al., 2009; Prince et al., 2014).

Increasing PDE4A5 in the hippocampus attenuates the formation of long-term context–shock associations

We first assessed whether selective overexpression of PDE4A5 in hippocampal neurons attenuates long-term memory formation of context–shock associations. Increased PDE4A5 protein in the hippocampus did not affect freezing levels during training (eGFP, $n = 14$; PDE4A5, $n = 14$; preshock, $t_{(26)} = 0.83$, $p > 0.40$;

postshock, $t_{(26)} = -0.20$, $p > 0.84$; Fig. 4A) but resulted in reduced freezing levels during re-exposure to the training context 24 h after conditioning (eGFP, $41.9 \pm 2.7\%$; PDE4A5, $29.3 \pm 3.0\%$; $t_{(26)} = 3.06$, $p = 0.005$; Fig. 4A). Because short-term contextual fear memories do not rely on cAMP signaling (Bourtchouladze et al., 1998), we hypothesized that PDE4A5 overexpression would not affect short-term memory formation for context–shock associations. Consistent with this, increasing PDE4A5 protein levels did not alter freezing levels during training (eGFP, $n = 9$; PDE4A5, $n = 9$; preshock, $t_{(16)} = -0.18$, $p = 0.85$; postshock, $t_{(16)} = 0.87$, $p = 0.39$; Fig. 4B), or the findings of a retention test 1 h after training ($t_{(16)} = 0.48$, $p > 0.85$, $p = 0.64$; Fig. 4B). Thus, increasing PDE4A5 protein levels specifically affects the consolidation of long-term contextual fear memories.

Tone-cued fear conditioning is a task in which rodents associate a tone [conditioned stimulus (CS)] with a mild electrical shock (unconditioned stimulus), a process that requires the amygdala rather than the hippocampus (LeDoux, 2000). Mice (eGFP, $n = 12$; PDE4A5, $n = 13$) overexpressing PDE4A5 expressed similar freezing levels during the conditioning (preshock, $t_{(23)} = 0.80$, $p = 0.43$; CS; $t_{(23)} = 1.06$, $p = 0.30$; postshock, $t_{(23)} = 0.54$, $p = 0.60$; Fig. 4C). Twenty-four hours after training, mice were exposed to a novel context and re-exposed to the CS. Both groups showed similar freezing levels during exposure to the novel context ($t_{(23)} = -0.66$, $p = 0.51$; Fig. 4C), and exposure to the CS ($t_{(23)} = 0.26$, $p = 0.80$; Fig. 4C). Thus, tone-cued fear conditioning is not affected by the overexpression of PDE4A5 in hippocampal neurons.

PDE4A5 differs from other isoforms by virtue of a 102 aa unique N-terminal targeting domain (Beard et al., 2002; Bolger et al., 2003). To determine whether PDE4A5 requires this domain

to target signaling complexes critical for the formation of context–shock associations, we engineered a truncated version of PDE4A5^{Δ4} that lacks the first 303 bp encoding the PDE4A5^{Δ4} (Bolger et al., 2003) and virally expressed this N-terminally truncated species in hippocampal neurons. In contrast to full-length PDE4A5, this truncated version failed to impair long-term memory for context–shock associations ($t_{(15)} = -1.10$, $p > 0.28$; Fig. 4D). To further assess the specificity of the PDE4A5-mediated long-term memory deficit, we replicated the experiment, but now increased the levels of the PDE4A1 isoform. This short PDE4A isoform is exclusively membrane associated, with a major fraction of PDE4A1 found compartmentalized to the Golgi (Shakur et al., 1995; Pooley et al., 1997). In contrast to the increased expression of PDE4A5, elevated protein levels of PDE4A1 in hippocampal neurons did not




Figure 2. Overexpression of PDE4A5 in hippocampal excitatory neurons reduces cAMP levels in the hippocampus. **A**, Viral expression of PDE4A5 reduces cAMP levels in the hippocampus, but not in the prefrontal cortex or cerebellum. **B**, **C**, Representative cAMP immunoreactivity images in mice expressing eGFP or overexpressing PDE4A5. Note the reduction in cAMP immunoreactivity in the major hippocampal subregions, but not in the amygdala. All error bars denote SEM. * $p < 0.05$, ** $p = 0.01$.

affect long-term memory formations ($t_{(13)} = -1.25$, $p > 0.23$; Fig. 4D). Together, these findings indicate that the unique N-terminal region of PDE4A5 confers the functional targeting of a core catalytic PDE4A module to a critical signaling complex in hippocampal excitatory neurons involved in regulating the formation of long-term contextual fear memories where it determines spatially localized cAMP degradation.

Overexpression of PDE4A5 in hippocampal excitatory neurons attenuates the consolidation of long-term object–place memories

To examine the impact of PDE4A5 overexpression on a nonaversive hippocampus-dependent task, we turned to the object–location memory paradigm in which mice have to learn and remember the location of individual objects (Oliveira et al., 2010; Havekes et al., 2014). Mice expressing eGFP ($n = 14$) or PDE4A5 ($n = 15$) gradually reduced object exploration levels across the training sessions, indicating that animals acquired the locations of the individual objects (eGFP: session 1, 18.9 ± 1.3 s; session 2, 13.0 ± 1.2 s; session 3, 13.2 ± 2.0 s; PDE4A5: session 1, 24.1 ± 2.2 s; session 2, 18.4 ± 1.8 s; session 3, 13.7 ± 1.7 s; ANOVA effect of session, $F_{(2,54)} = 34.9$, $p = 0.0001$). Overall, PDE4A5 mice showed slightly elevated exploration levels (ANOVA, effect of virus, $F_{(1,27)} = 4.756$, $p = 0.038$). During the test session 24 h after training, eGFP mice preferentially explored the displaced object, indicating that they successfully remembered the previous location of the individual objects. In contrast, mice overexpressing PDE4A5 explored all objects to a similar extent, which is indicative of a poor memory for the original object locations (eGFP, $49.8 \pm 5.2\%$; PDE4A5, $31.3 \pm 3.1\%$; $t_{(27)} = 3.11$; $p = 0.004$; Fig. 4E).

The novel object recognition task is based on the natural tendency of rodents to explore novel objects (Ennaceur and Delacour, 1988; Oliveira et al., 2010). Because the training conditions we use do not require an intact hippocampus (Oliveira et al., 2010), we anticipated that object–identity memories should not be affected by the overexpression of PDE4A5 in hippocampal neurons. During training, eGFP ($n = 8$) and PDE4A5 ($n = 10$) mice showed no preference for either object (Fig. 4F), although the total object exploration levels were elevated in the mice overexpressing PDE4A5 (eGFP, $20.9 \pm 1.1\%$; PDE4A5, $31.3 \pm 3.1\%$; $t_{(16)} = -3.923$; $p < 0.005$). During the test session 24 h after training, both groups preferentially explored the novel object, indicating that they successfully discriminated the novel object from the familiar object (ANOVA, effect of object preference: $F_{(1,16)} = 18.623$, $p = 0.001$; ANOVA, effect of virus: $F_{(1,16)} = 0.274$, $p = 0.608$; interaction effect, $F_{(1,16)} = 0.013$, $p = 0.912$; Fig. 4F).

To determine whether N-terminal-mediated targeting of PDE4A5 was essential for the ability of PDE4A5 to regulate the formation of object–place memories, we again expressed the N-terminal truncated form of PDE4A5, referred to as PDE4A5^{Δ4}, in hippocampal neurons and trained mice in the object–location memory task. During the retention test and then some 24 h after training, both groups preferentially explored the displaced object (eGFP, $n = 8$; PDE4A5^{Δ4}, $n = 9$; ANOVA, effect of object: $F_{(1,15)} = 25.217$, $p = 0.0001$; ANOVA, effect of virus: $F_{(1,15)} = 0.36$, $p = 0.852$; Fig. 4G). Next, we assessed whether elevated expression of the short PDE4A isoform PDE4A1, which targets the Golgi (Shakur et al., 1995; Pooley et al., 1997), would similarly attenuate the formation of object–location memories. In line with our fear-conditioning results, increased expression of




Figure 3. Overexpression of PDE4A5 in hippocampal excitatory neurons reduces forskolin-induced potentiation. **A**, Input–output curves relating the amplitude of the presynaptic fiber volley to the initial slope of the corresponding fEPSP at various stimulus intensities was not altered due to viral overexpression of PDE4A5 in hippocampal neurons. **B**, PDE4A5 overexpression does not change paired-pulse facilitation, a short-term form of synaptic plasticity, in hippocampal slices. **C**, Elevated expression of PDE4A5 in hippocampal neurons attenuates LTP induced by bath application with the adenylate cyclase activator forskolin. The mean fEPSP slope over the last 20 min of the recording was significantly reduced in PDE4A5 mice. In all sample sweeps, black traces indicate baseline, and red traces were acquired at 1 h after tetanus injection. All error bars denote SEM.

PDE4A1 did not affect the formation of object–location memories (eGFP, $n = 8$; PDE4A1, $n = 7$; ANOVA, effect of object: $F_{(1,13)} = 63.271$, $p = 0.0001$; ANOVA, effect of virus: $F_{(1,13)} = 0.277$, $p = 0.608$; Fig. 4G). The latter finding suggests that PDE4A1 does not target protein complexes critical for the formation of object–location memories. These data imply that PDE4A5 negatively impacts the formation of object–location memories by involving protein–protein interactions that target its unique N-terminal domain.

In a final set of behavioral studies, we determined whether the memory deficits associated with PDE4A5 expression could be a result of behavioral abnormalities unrelated to memory formation. Hippocampal overexpression of PDE4A5 does not affect explorative behavior or anxiety levels in, respectively, an open field (eGFP, $n = 6$; PDE4A5, $n = 8$; $t_{(12)} = -1.44$; $p = 0.175$; Fig. 4H) and a zero maze (eGFP, $n = 9$; PDE4A5, $n = 10$; $t_{(17)} = 0.653$; $p = 0.523$; Fig. 4I). Thus, our behavioral studies indicate that the N-terminal targeting domain of PDE4A5 plays an essential role in the targeting of cAMP signaling that is critical for long-term memory formation.

Full-length PDE4A5 but not truncated PDE4A5 attenuates forskolin-mediated FRET cAMP responses

Because our behavioral studies suggested that the N-terminal domain plays an essential role in the compartmentalization of

PDE4A5, we measured cAMP responses using the ICUE3 biosensor in hippocampal neurons expressing a control vector, full-length PDE4A5, or the N-terminal domain lacking PDE4A5 $^{\Delta 4}$. Baseline FRET responses were not affected by the overexpression of either construct (ANOVA, effect of construct: $F_{(2,44)} = 1.984$, $p = 0.198$; Fig. 5A,B). The expression of PDE4A5, but not PDE4A5 $^{\Delta 4}$, attenuated the forskolin-mediated FRET response (ANOVA, effect of construct: $F_{(2,44)} = 11.991$, $p < 0.0001$; PDE4A5 vs control, Tukey test, $p < 0.001$; PDE4A5 vs PDE4A5 $^{\Delta 4}$, Tukey test, $p = 0.001$; Fig. 5A,B). Consecutive bath application with the PDE inhibitor IBMX normalized the FRET responses (ANOVA, effect of construct, $F_{(2,44)} = 0.295$, $p = 0.746$; Fig. 5A,B), indicating that the decrease in FRET response due to the overexpression of PDE4A5 was not a result of nonspecific alterations in PDE/cAMP signaling. Together, these data indicate that the N-terminal domain of PDE4A5 plays a critical role in the localization of PDE4A5 to specific intracellular domains, where it hampers local cAMP-dependent processes critical for synaptic plasticity and memory.

The N-terminal domain of PDE4A5 plays an essential role in the compartmentalization of PDE isoforms

Our behavioral data suggest that the N-terminal domain of PDE4A5 plays an essential role in the compartmentalization of the PDE4A5 isoform to cAMP-containing complexes that are critical for learning and memory. Therefore, we virally expressed full-length and truncated N-terminal-lacking PDE4A5 in cultured hippocampal neurons to compare the intracellular distribution of these isoforms. We found that the focus of full-length PDE4A5 immunofluorescence in the cultured neurons is in both a discrete perinuclear area and in dendritic compartments (Fig. 6, left). In contrast, truncated PDE4A5 lacking the N-terminal domain unique for this isoform was located predominantly in the perinuclear region (Fig. 6, middle). These findings confirm previous work (Houslay et al., 1998; Huston et al., 2000) highlighting the importance of isoform unique N-terminal domains in determining the intracellular distribution of PDE4A enzymes.

Discussion

Phosphodiesterases play an essential role in orchestrating the compartmentalized degradation of cAMP, leading to local changes in cAMP signaling in specific subcellular domains in the cell (Houslay, 2010). This is in part achieved by isoform-specific N-terminal domains that bind to specific localized protein complexes, which enable individual PDE isoforms to target local cAMP signaling and thereby to regulate a unique set of molecular processes (Houslay, 2010). The PDE4A5 isoform has a unique 102 aa N-terminal region involved in its intracellular targeting (Beard et al., 2002; Bolger et al., 2003). Using a viral approach, we




Figure 4. Localization of PDE4A5 by the unique N-terminal domain plays a central role in the memory deficits associated with the overexpression of PDE4A5. **A**, Overexpression of PDE4A5 in hippocampal neurons impairs the formation of long-term memories for context–fear associations without affecting freezing levels during training. **B**, In contrast, elevated PDE4A5 protein levels in hippocampal neurons do not change the formation of short-term contextual fear memories. **C**, PDE4A5 overexpression in hippocampal neurons does not alter the consolidation of amygdala-dependent tone-cued fear memories and also did not affect freezing levels during training in either fear-conditioning paradigm. **D**, Overexpression of a truncated form of PDE4A5, PDE4A5 Δ 4, that lacks the isoform-unique N-terminal domain or the short isoform PDE4A1 in hippocampal neurons does not alter the formation of long-term contextual fear memories. **E**, Increasing expression of PDE4A5 in hippocampal excitatory neurons impairs memory consolidation for object–location. **F**, In contrast, increasing PDE4A5 protein levels in the hippocampus leaves the consolidation of long-term memories for object identity undisturbed. **G**, Overexpression of the N-terminal-lacking PDE4A5 Δ 4 or the short isoform PDE4A1 in hippocampal neurons does not modulate memory consolidation for object location. **H**, **I**, Elevated expression of PDE4A5 in hippocampal excitatory neurons does not alter exploratory behavior in an open field task or anxiety levels in the zero maze task. The dotted line indicates no preference. All error bars denote SEM. ** $p = 0.01$ *** $p = 0.005$.

show that increased selective expression of PDE4A5 in hippocampal excitatory neurons attenuates a cAMP-dependent form of synaptic plasticity in hippocampal area CA1, reduces forskolin-mediated increases in cAMP content in cultured hippocampal neurons, and impairs long-term memory formation specifically in learning tasks that require the hippocampus. Furthermore, to assess the role of the N-terminal domain of PDE4A5 in compartmentalizing and targeting cAMP-dependent signaling complexes that are critical for memory storage, we replicated the biochemical and behavioral studies using an N-terminal-lacking truncated version of the same protein. In contrast to the observations with full-length PDE4A5, the expression of the N-terminal truncated PDE4A5 construct does not attenuate forskolin-mediated alterations in cAMP responses in cultured neurons and does not

affect hippocampus-dependent forms of memory, but does alter the intracellular distribution of this isoform.

Our overexpression studies with full-length PDE4A5 and PDE4A1 as well as truncated PDE4A5 emphasize that increases in the protein levels of specific PDE4 isoforms initiates the decrease in cAMP levels in specific neuronal compartments rather than causing a global nonspecific decrease in cAMP throughout the cell. Our overexpression studies suggest that the common domains shared by the different PDE4 isoforms, including the catalytic domain and the conserved regulatory regions 1 and 2 (UCR1 and UCR2), do not likely contribute to the hippocampus-dependent cognitive deficits associated with PDE4A5 overexpression. The lack of an impact of the N-terminal-lacking PDE4A5 isoform at the behavioral




Figure 5. Full-length but not truncated PDE4A5 attenuates FK-mediated cAMP responses assessed by a FRET indicator. *A*, FRET cAMP responses were measured in cultured hippocampal neurons expressing a control construct, PDE4A5, or truncated N-terminal domain-lacking PDE4A5 $\Delta 4$ after consecutive bath application with the adenylate cyclase activator FK and phosphodiesterase inhibitor IBMX. Forskolin treatment significantly elevated cAMP levels in control neurons and neurons expressing PDE4A5 $\Delta 4$, whereas the cAMP response was attenuated in neurons overexpressing full-length PDE4A5. *B*, Average FRET sensor responses for the different treatment conditions. Baseline FRET responses were not affected by the overexpression of either construct. The expression of PDE4A5, but not PDE4A5 $\Delta 4$, attenuated the forskolin-mediated FRET response. Consecutive bath applications with the PDE inhibitor IBMX normalized the FRET responses. CT = 20 cells from three preparations; PDE4A5 = 11 cells from three preparations; PDE4A5 $\Delta 4$ = 14 cells from three preparations. All error bars denote SEM. *** $p \leq 0.001$.




Figure 6. Loss of the isoform-unique N-terminal domain alters the compartmentalization of PDE4A5 in hippocampal neurons. Full-length PDE4A5 is compartmentalized to both a discrete perinuclear area and dendritic compartments (left panels). In contrast, truncated PDE4A5 lacking the N-terminal domain that is unique for the isoform was located predominantly in the perinuclear region (middle panels). PDE4A5 expression is absent from the nucleus (right panels).

level is not likely to be explained by a reduction in the efficacy of the truncated isoform to degrade cAMP, as we previously shown that the loss of the isoform-specific N-terminal domain leads to an increase rather than a decrease in catalytic activity (Beard et al., 2002).

Our findings also reveal the importance of the isoform-specific N-terminal domain for targeting individual PDE4 isoforms to cAMP signaling that is critical for cognitive processes, and confirms and expands on previous *in vitro* work showing that truncation of the N-terminal region of PDE4A5 alters its membrane association and localization at the cell margin (Huston et

al., 2000; Beard et al., 2002; Bolger et al., 2003; Houslay, 2010). At the membrane, PDE4 isoforms can interact with molecular elements that are critical for learning and memory, such as β arrestins (Li et al., 2009). The unique N-terminal domain of PDE4A5 also allows for association with certain SH3 domain-containing proteins, such as certain members of the src tyrosyl kinase family, including Src, Fyn, and Lyn (Beard et al., 1999, 2002), and recent work indicates that Fyn inhibition reverses memory deficits in mouse models for Alzheimer's disease (Kaufman et al., 2015). PDE4A5 also interacts with Disrupted-in-Schizophrenia 1 (DISC1; Murdoch et al., 2007), a major risk factor for schizophre-

nia and other psychiatric diseases, such as bipolar disorder and depression (Porteous and Millar, 2006). Therefore, the misregulation of DISC1-related signaling mechanisms may contribute to the endophenotypes associated with the overexpression of PDE4A5. The N-terminal domain of PDE4A5 also binds the immunophilin XAP2 (also called AIP and ARA9; Bolger et al., 2003), although, to our knowledge, no studies have examined the role of XAP2 in learning and memory. Deletion of the unique part of the N-terminal domain also disrupts the focus of PDE4A5 localization within ruffles at the cell margin (Beard et al., 2002). Because membrane ruffles play an essential role in cell motility and spine dynamics and through the remodeling of the actin cytoskeleton (Chhabra and Higgs, 2007; Honkura et al., 2008), one additional mechanism through which PDE4A5 could affect memory formation is by negatively impacting cAMP-dependent signaling mechanisms that modulate actin dynamics. Future studies including coimmunoprecipitation and colocalization experiments with the N-terminal domain-binding proteins will have to define whether these candidate mechanisms indeed contribute to the plasticity deficits and memory impairments associated with elevated expression of this isoform.

Sleep deprivation negatively impacts cognitive processes, particularly those that require the hippocampus (Havekes et al., 2012a; Abel et al., 2013; Kreutzmann et al., 2015). We previously found that a single brief period of sleep deprivation elevated PDE4 activity and reduced cAMP levels in the hippocampus. These changes were accompanied by a specific increase in PDE4A5 protein expression without affecting the protein levels of other PDE4 isoforms, such as PDE4B, PDE4D3, and PDE4D5 (Vecsey et al., 2009). The memory deficits associated with a single 5 h period of sleep deprivation could be prevented by pharmacological inhibition of the PDE4 family (Vecsey et al., 2009) and by transiently increasing cAMP levels selectively in hippocampal neurons (Havekes et al., 2014). Despite these observations, it remains to be defined whether the increase in PDE4A5 function in the hippocampus was causally related to the memory and plasticity impairments associated with sleep loss. In our current study, we observed that increasing hippocampal PDE4A5 levels impairs long-term memory formation in contextual fear conditioning and object–place recognition tasks (Fig. 4). In both learning paradigms, the formation of long-term memories critically depends on proper hippocampal function (LeDoux, 2000; Oliveira et al., 2010), and the observed impairments in both tasks mimic those observed with sleep deprivation (Graves et al., 2003; Vecsey et al., 2009; Hagewoud et al., 2010; Florian et al., 2011; Havekes et al., 2012a, 2014; Abel et al., 2013). Using electrophysiological recordings, we show that increasing PDE4A5 protein levels impairs forskolin-induced synaptic plasticity (Fig. 3), a deficit that also occurs after 5 h of sleep deprivation (Vecsey et al., 2009). In summary, this work reveals that the elevated expression of the PDE4A5 isoform in hippocampal neurons is sufficient to mimic electrophysiological and cognitive phenotypes associated with sleep loss.

To our knowledge, this work is the first to define the function of the PDE4A5 isoform and protein domains in hippocampal function. From a broader perspective, our work will help to define the contribution of individual PDE isoforms to the endophenotypes of neurocognitive and neuropsychiatric disorders that are accompanied by altered PDE signaling and facilitate the development of novel therapeutic strategies based on the targeting of specific domains of individual PDE isoforms. Related to this notion, there is now a wealth of evidence consistent with the idea that the evolutionary conserved diversity of N-terminal regions

that define specific PDE4 isoforms is related to their recruitment to specific signaling complexes (Houslay, 2010). We, and others, have demonstrated that such interactions can be disrupted using cell-permeable peptides and also that such species can phenocopy dominant-negative approaches (Smith et al., 2007; Serrels et al., 2010; Martin et al., 2014). Indeed, an engineered peptide disrupting PDE4D–HSP20 interactions shows *in vivo* efficacy in a mouse model of pressure overload-mediated hypertrophy (Martin et al., 2014). The ability to refine such disruptor peptides for *in vivo* use could be facilitated through the use of nuclear magnetic resonance to uncover their structure (Smith et al., 2007), together with the incorporation of non-native amino acids and the addition of lipid species to facilitate cell entry together with truncation and modification to generate peptidomimetic species. Identification of the functional anchor species for PDE4A5 in this scenario would then take developments to a level where high-throughput screening for small-molecule, drug-like disruptor species of PDE4A5 and its functional anchor becomes a realistic approach. Additionally, high content screens for compounds that dislocate PDE4A5 from its relevant compartment in cells would provide another means of such compounds. The aim would be to uncover small peptides and peptidomimetics of small molecules that enter the brain and dislocate PDE4A5 from the functionally relevant anchor protein/signaling complex to recapitulate the phenotype we describe in these studies.

References

- Abel T, Havekes R, Saletin JM, Walker MP (2013) Sleep, plasticity and memory from molecules to whole-brain networks. *Curr Biol* 23:R774–R788. [CrossRef Medline](#)
- Barad M, Bourthouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. *Proc Natl Acad Sci U S A* 95:15020–15025. [CrossRef Medline](#)
- Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, Heeke GV (2004) Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. *Am J Physiol Lung Cell Mol Physiol* 287:L332–L343. [CrossRef Medline](#)
- Beard MB, O'Connell JC, Bolger GB, Houslay MD (1999) The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. *FEBS Lett* 460:173–177. [CrossRef Medline](#)
- Beard MB, Huston E, Campbell L, Gall I, McPhee I, Yarwood S, Scotland G, Houslay MD (2002) In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. *Cell Signal* 14:453–465. [CrossRef Medline](#)
- Bertolino A, Crippa D, di Dio S, Fichte K, Musmeci G, Porro V, Rapisarda V, Sastre-y-Hernández M, Schratz M (1988) Rolipram versus imipramine in inpatients with major, “minor” or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. *Int Clin Psychopharmacol* 3:245–253. [CrossRef Medline](#)
- Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD (2003) Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. *J Biol Chem* 278:33351–33363. [CrossRef Medline](#)
- Bourthouladze R, Abel T, Berman N, Gordon R, Lapidus K, Kandel ER (1998) Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. *Learn Mem* 5:365–374. [Medline](#)
- Braun NN, Reutiman TJ, Lee S, Folsom TD, Fatemi SH (2007) Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. *Neuroreport* 18:1841–1844. [CrossRef Medline](#)
- Chhabra ES, Higgs HN (2007) The many faces of actin: matching assembly factors with cellular structures. *Nat Cell Biol* 9:1110–1121. [CrossRef Medline](#)
- Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phos-

- phodiesterases. *Prog Nucleic Acid Res Mol Biol* 63:1–38. [CrossRef Medline](#)
- Crinion SJ, McNicholas WT (2014) Sleep-related disorders in chronic obstructive pulmonary disease. *Expert Rev Respir Med* 8:79–88. [CrossRef Medline](#)
- DiPilato LM, Zhang J (2009) The role of membrane microdomains in shaping beta2-adrenergic receptor-mediated cAMP dynamics. *Mol Biosyst* 5:832–837. [CrossRef Medline](#)
- Dittgen T, Nimmerjahn A, Komai S, Licznarski P, Waters J, Margrie TW, Helmchen F, Denk W, Brecht M, Osten P (2004) Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. *Proc Natl Acad Sci U S A* 101:18206–18211. [CrossRef Medline](#)
- D'Sa C, Eisch AJ, Bolger GB, Duman RS (2005) Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. *Eur J Neurosci* 22:1463–1475. [CrossRef Medline](#)
- Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, Fujiwara M (1997) Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. *Jpn J Pharmacol* 75:275–281. [CrossRef Medline](#)
- Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. *Behav Brain Res* 31:47–59. [CrossRef Medline](#)
- Fatemi SH, Reutiman TJ, Folsom TD, Lee S (2008a) Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder. *Psychiatr Genet* 18:282–288. [CrossRef Medline](#)
- Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga SA, Conti M, Menniti FS (2008b) PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. *Schizophrenia Res* 101:36–49. [CrossRef Medline](#)
- Florian C, Vecsey CG, Halassa MM, Haydon PG, Abel T (2011) Astrocyte-derived adenosine and A1 receptor activity contribute to sleep loss-induced deficits in hippocampal synaptic plasticity and memory in mice. *J Neurosci* 31:6956–6962. [CrossRef Medline](#)
- Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. *J Clin Invest* 114:1624–1634. [CrossRef Medline](#)
- Graves LA, Heller EA, Pack AI, Abel T (2003) Sleep deprivation selectively impairs memory consolidation for contextual fear conditioning. *Learn Mem* 10:168–176. [CrossRef Medline](#)
- Hagewoud R, Whitcomb SN, Heeringa AN, Havekes R, Koolhaas JM, Meerlo P (2010) A time for learning and a time for sleep: the effect of sleep deprivation on contextual fear conditioning at different times of the day. *Sleep* 33:1315–1322. [Medline](#)
- Hansen RT 3rd, Conti M, Zhang HT (2014) Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior. *Psychopharmacology* 231:2941–2954. [CrossRef Medline](#)
- Havekes R, Abel T (2009) Genetic dissection of neural circuits and behavior in *Mus musculus*. *Adv Genet* 65:1–38. [CrossRef Medline](#)
- Havekes R, Timmer M, Van der Zee EA (2007) Regional differences in hippocampal PKA immunoreactivity after training and reversal training in a spatial Y-maze task. *Hippocampus* 17:338–348. [CrossRef Medline](#)
- Havekes R, Vecsey CG, Abel T (2012a) The impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticity. *Cell Signal* 24:1251–1260. [CrossRef Medline](#)
- Havekes R, Canton DA, Park AJ, Huang T, Nie T, Day JP, Guercio LA, Grimes Q, Luczak V, Gelman IH, Baillie GS, Scott JD, Abel T (2012b) Gravin orchestrates protein kinase A and β 2-adrenergic receptor signaling critical for synaptic plasticity and memory. *J Neurosci* 32:18137–18149. [CrossRef Medline](#)
- Havekes R, Bruinenberg VM, Tudor JC, Ferri SL, Baumann A, Meerlo P, Abel T (2014) Transiently increasing cAMP levels selectively in hippocampal excitatory neurons during sleep deprivation prevents memory deficits caused by sleep loss. *J Neurosci* 34:15715–15721. [CrossRef Medline](#)
- Honkura N, Matsuzaki M, Noguchi J, Ellis-Davies GC, Kasai H (2008) The subspine organization of actin fibers regulates the structure and plasticity of dendritic spines. *Neuron* 57:719–729. [CrossRef Medline](#)
- Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. *Trends Biochem Sci* 35:91–100. [CrossRef Medline](#)
- Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. *Biochem J* 370:1–18. [CrossRef Medline](#)
- Houslay MD, Sullivan M, Bolger GB (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. *Adv Pharmacol* 44:225–342. [CrossRef Medline](#)
- Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. *Circ Res* 100:950–966. [CrossRef Medline](#)
- Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, Houslay MD (2000) The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. *J Biol Chem* 275:28063–28074. [CrossRef Medline](#)
- Isiegas C, McDonough C, Huang T, Havekes R, Fabian S, Wu LJ, Xu H, Zhao MG, Kim JJ, Lee YS, Lee HR, Ko HG, Lee N, Choi SL, Lee JS, Son H, Zhuo M, Kaang BK, Abel T (2008) A novel conditional genetic system reveals that increasing neuronal cAMP enhances memory and retrieval. *J Neurosci* 28:6220–6230. [CrossRef Medline](#)
- Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nygaard HB, Strittmatter SM (2015) Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. *Ann Neurol* 77:953–971. [CrossRef Medline](#)
- Kreutzmann JC, Havekes R, Abel T, Meerlo P (2015) Sleep deprivation and hippocampal vulnerability: changes in neuronal plasticity, neurogenesis and cognitive function. *Neuroscience* 309:173–190. [CrossRef Medline](#)
- LeDoux JE (2000) Emotion circuits in the brain. *Annu Rev Neurosci* 23:155–184. [CrossRef Medline](#)
- Li Y, Li H, Liu X, Bao G, Tao Y, Wu Z, Xia P, Wu C, Li B, Ma L (2009) Regulation of amygdalar PKA by beta-arrestin-2/phosphodiesterase-4 complex is critical for fear conditioning. *Proc Natl Acad Sci U S A* 106:21918–21923. [CrossRef Medline](#)
- Li YF, Cheng YF, Huang Y, Conti M, Wilson SP, O'Donnell JM, Zhang HT (2011) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. *J Neurosci* 31:172–183. [CrossRef Medline](#)
- Martin TP, Hortigon-Vinagre MP, Findlay JE, Elliott C, Currie S, Baillie GS (2014) Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. *FEBS Open Bio* 4:923–927. [CrossRef Medline](#)
- Mika D, Leroy J, Vandecasteele G, Fischmeister R (2012) PDEs create local domains of cAMP signaling. *J Mol Cell Cardiol* 52:323–329. [CrossRef Medline](#)
- Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klusmann E, Porteous DJ, Millar JK, Houslay MD (2007) Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. *J Neurosci* 27:9513–9524. [CrossRef Medline](#)
- Neves G, Cooke SF, Bliss TV (2008) Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. *Nat Rev Neurosci* 9:65–75. [CrossRef Medline](#)
- O'Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol Sci* 25:158–163. [CrossRef Medline](#)
- Oliva AA Jr, Kang Y, Furones C, Alonso OF, Bruno O, Dietrich WD, Atkins CM (2012) Phosphodiesterase isoform-specific expression induced by traumatic brain injury. *J Neurochem* 123:1019–1029. [CrossRef Medline](#)
- Oliveira AM, Hawk JD, Abel T, Havekes R (2010) Post-training reversible inactivation of the hippocampus enhances novel object recognition memory. *Learn Mem* 17:155–160. [CrossRef Medline](#)
- Park AJ, Havekes R, Choi JH, Luczak V, Nie T, Huang T, Abel T (2014) A presynaptic role for PKA in synaptic tagging and memory. *Neurobiol Learn Mem* 114:101–112. [CrossRef Medline](#)
- Park H, Lee JA, Lee C, Kim MJ, Chang DJ, Kim H, Lee SH, Lee YS, Kaang BK (2005) An *Aplysia* type 4 phosphodiesterase homolog localizes at the presynaptic terminals of *Aplysia* neuron and regulates synaptic facilitation. *J Neurosci* 25:9037–9045. [CrossRef Medline](#)
- Pooley L, Shakur Y, Rena G, Houslay MD (1997) Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1

- (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. *Biochem J* 321:177–185. [CrossRef Medline](#)
- Porteous DJ, Millar JK (2006) Disrupted in schizophrenia 1: building brains and memories. *Trends Mol Med* 12:255–261. [CrossRef Medline](#)
- Prince TM, Wimmer M, Choi J, Havekes R, Aton S, Abel T (2014) Sleep deprivation during a specific 3-hour time window post-training impairs hippocampal synaptic plasticity and memory. *Neurobiol Learn Mem* 109:122–130. [CrossRef Medline](#)
- Randt CT, Judge ME, Bonnet KA, Quartermain D (1982) Brain cyclic AMP and memory in mice. *Pharmacol Biochem Behav* 17:677–680. [CrossRef Medline](#)
- Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. *Psychopharmacology* 202:419–443. [CrossRef Medline](#)
- Richter W, Menniti FS, Zhang HT, Conti M (2013) PDE4 as a target for cognition enhancement. *Expert Opin Ther Targets* 17:1011–1027. [CrossRef Medline](#)
- Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC (2002) Assessing the emetic potential of PDE4 inhibitors in rats. *Br J Pharmacol* 135:113–118. [CrossRef Medline](#)
- Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, Wallace TL (2008) Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. *Eur J Neurosci* 28:625–632. [CrossRef Medline](#)
- Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E, Steinbusch HW, Kelly PA, Prickaerts JH (2009) Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. *Neuropsychopharmacology* 34:1914–1925. [CrossRef Medline](#)
- Sanderson TM, Sher E (2013) The role of phosphodiesterases in hippocampal synaptic plasticity. *Neuropharmacology* 74:86–95. [CrossRef Medline](#)
- Serrels B, Sandilands E, Serrels A, Baillie G, Houslay MD, Brunton VG, Canel M, Machesky LM, Anderson KI, Frame MC (2010) A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. *Curr Biol* 20:1086–1092. [CrossRef Medline](#)
- Shakur Y, Wilson M, Pooley L, Lobban M, Griffiths SL, Campbell AM, Beattie J, Daly C, Houslay MD (1995) Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. *Biochem J* 306:801–809. [CrossRef Medline](#)
- Siuciak JA, McCarthy SA, Chapin DS, Martin AN (2008) Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. *Psychopharmacology* 197:115–126. [CrossRef Medline](#)
- Smith KJ, Baillie GS, Hyde EI, Li X, Houslay TM, McCahill A, Dunlop AJ, Bolger GB, Klusmann E, Adams DR, Houslay MD (2007) 1H NMR structural and functional characterization of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1. *Cell Signal* 19:2612–2624. [CrossRef Medline](#)
- Spina D (2008) PDE4 inhibitors: current status. *Br J Pharmacol* 155:308–315. [CrossRef Medline](#)
- Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS (1999) Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. *J Neurosci* 19:610–618. [Medline](#)
- Titus DJ, Sakurai A, Kang Y, Furones C, Jergova S, Santos R, Sick TJ, Atkins CM (2013) Phosphodiesterase inhibition rescues chronic cognitive deficits induced by traumatic brain injury. *J Neurosci* 33:5216–5226. [CrossRef Medline](#)
- Tretter V, Revilla-Sanchez R, Houston C, Terunuma M, Havekes R, Florian C, Jurd R, Vithlani M, Michels G, Couve A, Sieghart W, Brandon N, Abel T, Smart TG, Moss SJ (2009) Deficits in spatial memory correlate with modified {gamma}-aminobutyric acid type A receptor tyrosine phosphorylation in the hippocampus. *Proc Natl Acad Sci U S A* 106:20039–20044. [CrossRef Medline](#)
- Vecsey CG, Baillie GS, Jaganath D, Havekes R, Daniels A, Wimmer M, Huang T, Brown KM, Li XY, Descalzi G, Kim SS, Chen T, Shang YZ, Zhuo M, Houslay MD, Abel T (2009) Sleep deprivation impairs cAMP signalling in the hippocampus. *Nature* 461:1122–1125. [CrossRef Medline](#)
- Werenicz A, Christoff RR, Blank M, Jobim PF, Pedroso TR, Reolon GK, Schröder N, Roesler R (2012) Administration of the phosphodiesterase type 4 inhibitor rolipram into the amygdala at a specific time interval after learning increases recognition memory persistence. *Learn Mem* 19:495–498. [CrossRef Medline](#)
- Wiescholleck V, Manahan-Vaughan D (2012) PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. *Transl Psychiatry* 2:e89. [CrossRef Medline](#)
- Wimmer ME, Hernandez PJ, Blackwell J, Abel T (2012) Aging impairs hippocampus-dependent long-term memory for object location in mice. *Neurobiol Aging* 33:2220–2224. [CrossRef Medline](#)
- Zeller E, Stief HJ, Pflug B, Sastre-y-Hernández M (1984) Results of a phase II study of the antidepressant effect of rolipram. *Pharmacopsychiatry* 17:188–190. [CrossRef Medline](#)
- Zhang HT, O'Donnell JM (2000) Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. *Psychopharmacology* 150:311–316. [CrossRef Medline](#)
- Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O'Donnell JM (2008) Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). *Neuropsychopharmacology* 33:1611–1623. [CrossRef Medline](#)